Summary: first-line treatment of mBC with Avastin significantly prolongs PFS(The time from trial entry to disease progression or death from any cause) in combination with paclitaxel or Xeloda
Avastin: proven to double PFS to more than 11 months in combination with paclitaxel in first-line mBC
Avastin: proven to double PFS to more than 11 months in combination with paclitaxel in first-line mBC
- Median PFS improved from 5.8 to 11.3 months (HR(An estimate of relative risk of an event occurring)=0.48 [95% CI(A range of values used to indicate the reliability of an estimate (or a set of values within which there is a specified probability)): 0.39–0.61]; p<0.0001; by independent review facility [IRF] assessment).1
E2100: IRF confirmed results from investigator assessment of PFS in patients with mBC treated with first-line paclitaxel with or without Avastin1
Adapted from: Gray R, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27(30):4970. Reprinted with permission. © 2010 American Society of Clinical Oncology. All rights reserved.
Avastin with paclitaxel consistently improves PFS across relevant patient subgroups.1,2
Avastin with paclitaxel more than doubles ORR(The proportion of patients with defined tumour shrinkage; generally the sum of partial responses plus complete responses) in first-line mBC
- Paclitaxel alone: 22%; Avastin plus paclitaxel: 50% (by IRF assessment).3
Median PFS for Avastin plus paclitaxel in E2100 is comparable to the median TTP(The time from when a patient enters a study and the time that either the disease progresses (advances) or the patient dies) observed in the real-life setting.4*
*Refers to data with Avastin plus paclitaxel from the open-label(A type of clinical trial in which both the researchers and participants know which treatment is being administered) ATHENA study; other taxane-based chemotherapies studied in ATHENA are not included in the current label for Avastin.
Avastin in combination with Xeloda significantly improved PFS by 50% with limited impact on side effects of chemotherapy in first-line mBC
Median PFS was significantly improved from 5.7 to 8.6 months when Avastin was combined with Xeloda (HR=0.69 [95% CI: 0.56–0.84]; p<0.001.5
Avastin in combination with Xeloda significantly improves PFS by 50% with limited impact on side effects of chemotherapy in first-line mBC5
Adapted from: Robert NJ, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1255. Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
Avastin with Xeloda provides consistent improvements in PFS across relevant patient subgroups.5
Combining Avastin with Xeloda significantly increases ORR
- Xeloda alone: 23.6%; Avastin plus Xeloda: 35.4% (p=0.0097).5
References
- Gray R, Bhattacharya S, Bowden C, et al. J Clin Oncol 2009;27:4966–72.
- Cameron D. Eur J Cancer Suppl 2008;6:21–8.
- Klencke B, Bhattacharya S, Samant M, et al. J Clin Oncol 2008;26(May 20 Suppl.):50s (Abstract 1036 and associated poster presentation).
- Cortés-Funes H, Pritchard KI, Biganzoli L, et al. Eur J Cancer Suppl 2009;7:265 (Abstract 5017 and associated poster presentation).
- Robert NJ, Dieras V, Glaspy J, et al. J Clin Oncol 2011;29:1252–60.